Indivior (INDV) to Announce Earnings on Thursday

Indivior (NASDAQ:INDV) is anticipated to release its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Indivior to announce earnings of $0.8890 per share and revenue of $307.55 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 7:00 AM ET.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 EPS for the quarter. The business had revenue of $317.00 million for the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%. On average, analysts expect Indivior to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Indivior Price Performance

NASDAQ INDV opened at $40.45 on Thursday. The company’s fifty day moving average is $38.74 and its two-hundred day moving average is $35.26. The firm has a market capitalization of $4.93 billion, a price-to-earnings ratio of 20.74 and a beta of 0.86. Indivior has a 52-week low of $16.13 and a 52-week high of $42.81.

Analyst Ratings Changes

Several equities analysts recently issued reports on INDV shares. Weiss Ratings downgraded shares of Indivior from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, July 9th. Zacks Research cut shares of Indivior from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 29th. Finally, Barclays started coverage on Indivior in a research report on Thursday, June 18th. They set an “overweight” rating and a $46.00 price target on the stock. Five equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Indivior currently has an average rating of “Moderate Buy” and an average target price of $43.67.

Insiders Place Their Bets

In other news, insider Christian Heidbreder sold 18,586 shares of the business’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $41.14, for a total transaction of $764,628.04. Following the completion of the sale, the insider owned 209,337 shares in the company, valued at $8,612,124.18. The trade was a 8.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ryan Preblick sold 36,000 shares of the company’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $37.70, for a total value of $1,357,200.00. Following the transaction, the chief financial officer directly owned 284,751 shares in the company, valued at $10,735,112.70. This trade represents a 11.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.74% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in INDV. Goldman Sachs Group Inc. grew its holdings in shares of Indivior by 18.4% during the first quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock worth $79,757,000 after buying an additional 1,299,425 shares in the last quarter. Fuller & Thaler Asset Management Inc. increased its holdings in shares of Indivior by 101.0% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 6,371,534 shares of the company’s stock worth $228,611,000 after acquiring an additional 3,201,639 shares during the last quarter. State Street Corp raised its position in shares of Indivior by 65.5% in the fourth quarter. State Street Corp now owns 4,659,281 shares of the company’s stock valued at $167,175,000 after purchasing an additional 1,844,532 shares during the period. Rubric Capital Management LP lifted its position in Indivior by 31.6% during the second quarter. Rubric Capital Management LP now owns 4,647,179 shares of the company’s stock worth $68,499,000 after acquiring an additional 1,117,140 shares during the last quarter. Finally, Newtyn Management LLC lifted its holdings in Indivior by 61.1% during the 3rd quarter. Newtyn Management LLC now owns 4,200,000 shares of the company’s stock worth $101,262,000 after purchasing an additional 1,592,982 shares during the last quarter. Institutional investors and hedge funds own 60.33% of the company’s stock.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.